Renaissance Technologies
CLDI icon

Renaissance Technologies’s Calidi Biotherapeutics CLDI Stock Holding History

Renaissance Technologies’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-142
Closed -$26K – 3751
2023
Q4 		$26K Buy
+142
New +$38.1K ﹤0.01% 3553

Other funds holding CLDI

RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $315M AUM 19.93% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Renaissance Technologies's CLDI Position: Q1 2024 in Review

Renaissance Technologies sold out of Calidi Biotherapeutics (CLDI) in Q1 2024, closing a stake of 142 shares — an estimated $26K sold.

Renaissance Technologies first reported a position in CLDI in Q4 2023 and held it in 1 quarter. The position peaked at $26K in Q4 2023. 30 funds tracked by Wall St. Rank hold CLDI as of Q1 2024.

  • Renaissance Technologies reported no remaining Calidi Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Renaissance Technologies sold 142 Calidi Biotherapeutics shares in Q1 2024, an estimated $26K.
  • Renaissance Technologies first reported a position in Calidi Biotherapeutics in Q4 2023 and held it in 1 quarter.
  • Renaissance Technologies's Calidi Biotherapeutics position peaked at $26K in Q4 2023.
  • 30 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.